Zobrazeno 1 - 10 of 146 pro vyhledávání: '"Se, Halford"'
2
Carcinogenesis in MYH-Associated Polyposis Follows a Distinct Genetic Pathway
Autor: Lipton L, Se, Halford, Johnson V, Novelli MR, Jones A, Cummings C, Barclay E, Oliver Sieber, Sadat A, Ml, Bisgaard, Sv, Hodgson, La, Aaltonen, Hj, Thomas, Ip, Tomlinson
Publikováno v: Scopus-Elsevier
ResearcherID
Europe PubMed Central
Colorectal carcinomas develop according to particular genetic pathways, including the chromosomal instability (CIN+), microsatellite instability (MSI+) and MSI- CIN- routes. We have determined the genetic pathway in patients with MYH-associated polyp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::729ef8e063af3a1d65024ffbff8804cb
http://www.scopus.com/inward/record.url?eid=2-s2.0-10744220394&partnerID=MN8TOARS
Zobrazit plný text záznamu
3
Akademický článek
Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status.
Autor: Duabil AJ; Leicester Cancer Research Centre, Department of Genetics & Genome Biology, University of Leicester, LE1 7RH Leics, UK.; Department of Surgery, Faculty of Medicine, University of Kufa, Najaf, Iraq., Cooper CR; Leicester Cancer Research Centre, Department of Genetics & Genome Biology, University of Leicester, LE1 7RH Leics, UK.; MRC Oxford Institute for Radiation Oncology, University of Oxford, OX3 7DQ Oxon, UK., Aldujaily E; Leicester Cancer Research Centre, Department of Genetics & Genome Biology, University of Leicester, LE1 7RH Leics, UK.; Department of Pathology & Forensic Medicine, Faculty of Medicine, University of Kufa, Najaf, Iraq., Halford SE; Cancer Research UK Centre for Drug Development, London E20 1JQ, UK., Hirschberg S; Cancer Research UK Centre for Drug Development, London E20 1JQ, UK., Katugampola SD; Cancer Research UK Centre for Drug Development, London E20 1JQ, UK., Jones GD; Leicester Cancer Research Centre, Department of Genetics & Genome Biology, University of Leicester, LE1 7RH Leics, UK.
Publikováno v: Exploration of targeted anti-tumor therapy [Explor Target Antitumor Ther] 2023; Vol. 4 (5), pp. 1210-1226. Date of Electronic Publication: 2023 Dec 21.
Zobrazit plný text záznamu
4
Akademický článek
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
Autor: Rampling R; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Peoples S; Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, United Kingdom., Mulholland PJ; Department of Oncology, University College London Hospitals, London, United Kingdom., James A; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Al-Salihi O; Adult Neuro-Oncology, Southampton University Hospitals NHS Trust, Southampton, United Kingdom., Twelves CJ; Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, United Kingdom., McBain C; The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom., Jefferies S; Cambridge Cancer Trials Centre, Oncology Clinical Trials, Addensbrooke's Hospital, Cambridge, United Kingdom., Jackson A; Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom., Stewart W; Department of Neuropathology, The Queen Elizabeth University Hospital, Glasgow, United Kingdom., Lindner J; Immatics Biotechnologies GmbH, Tübingen, Germany., Kutscher S; Immatics Biotechnologies GmbH, Tübingen, Germany., Hilf N; Immatics Biotechnologies GmbH, Tübingen, Germany., McGuigan L; Cancer Research UK Centre for Drug Development, London, United Kingdom., Peters J; Cancer Research UK Centre for Drug Development, London, United Kingdom., Hill K; Cancer Research UK Centre for Drug Development, London, United Kingdom., Schoor O; Immatics Biotechnologies GmbH, Tübingen, Germany., Singh-Jasuja H; Immatics Biotechnologies GmbH, Tübingen, Germany., Halford SE; Cancer Research UK Centre for Drug Development, London, United Kingdom., Ritchie JW; Cancer Research UK Centre for Drug Development, London, United Kingdom. james.ritchie@cancer.org.uk.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Oct 01; Vol. 22 (19), pp. 4776-4785. Date of Electronic Publication: 2016 May 25.
Zobrazit plný text záznamu
5
Akademický článek
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Autor: Moreno L; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. CNIO, Madrid, Spain., Marshall LV; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. The Institute of Cancer Research, Sutton, United Kingdom., Pearson AD; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. The Institute of Cancer Research, Sutton, United Kingdom., Morland B; Birmingham Children's Hospital, Birmingham, United Kingdom., Elliott M; Leeds General Infirmary, Leeds, United Kingdom., Campbell-Hewson Q; Great North Children's Hospital, Newcastle, United Kingdom., Makin G; Institute of Cancer Sciences, Manchester Cancer Research Centre, Manchester Academic Health Sciences Centre, University of Manchester, and Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom., Halford SE; Drug Development Office, Cancer Research United Kingdom, London, United Kingdom., Acton G; Drug Development Office, Cancer Research United Kingdom, London, United Kingdom., Ross P; Drug Development Office, Cancer Research United Kingdom, London, United Kingdom., Kazmi-Stokes S; Drug Development Office, Cancer Research United Kingdom, London, United Kingdom., Lock V; Astex Therapeutics Ltd., Cambridge, United Kingdom., Rodriguez A; Astex Therapeutics Ltd., Cambridge, United Kingdom., Lyons JF; Astex Therapeutics Ltd., Cambridge, United Kingdom., Boddy AV; Northern Institute for Cancer Research, Newcastle, United Kingdom., Griffin MJ; Northern Institute for Cancer Research, Newcastle, United Kingdom., Yule M; Astex Therapeutics Ltd., Cambridge, United Kingdom., Hargrave D; Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. darren.hargrave@gosh.nhs.uk.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Jan 15; Vol. 21 (2), pp. 267-73. Date of Electronic Publication: 2014 Nov 04.
Zobrazit plný text záznamu
6
Akademický článek
TstI, a Type II restriction-modification protein with DNA recognition, cleavage and methylation functions in a single polypeptide.
Autor: Smith RM; The DNA-proteins Interaction Unit, School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK., Pernstich C; The DNA-proteins Interaction Unit, School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK., Halford SE; The DNA-proteins Interaction Unit, School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK s.halford@bristol.ac.uk.
Publikováno v: Nucleic acids research [Nucleic Acids Res] 2014 May; Vol. 42 (9), pp. 5809-22. Date of Electronic Publication: 2014 Mar 14.
Zobrazit plný text záznamu
7
Akademický článek
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Autor: Glasspool RM; The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK., Brown R; Department Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK., Gore ME; Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK., Rustin GJ; Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK., McNeish IA; St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK., Wilson RH; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AB, N. Ireland, UK., Pledge S; Sheffield Weston Park Hospital, Whitham Road, Sheffield, South Yorkshire S10 2SJ, UK., Paul J; The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK., Mackean M; Edinburgh Western General Hospital, Crewe Road S, Edinburgh EH4 2XU, UK., Hall GD; St James's Institute of Oncology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK., Gabra H; Department Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK., Halford SE; Drug Development Office Cancer Research UK, Angel Building, 407 Street, John Street, Islington, London EC1V 4AD, UK., Walker J; Analytical Services Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK., Appleton K; Analytical Services Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK., Ullah R; Analytical Services Unit, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK., Kaye S; Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.
Publikováno v: British journal of cancer [Br J Cancer] 2014 Apr 15; Vol. 110 (8), pp. 1923-9. Date of Electronic Publication: 2014 Mar 18.
Zobrazit plný text záznamu
8
Akademický článek
Accessibility, reactivity, and selectivity of side chains within a channel of de novo peptide assembly.
Autor: Burton AJ; School of Chemistry, University of Bristol, Bristol BS8 1TS, United Kingdom., Thomas F, Agnew C, Hudson KL, Halford SE, Brady RL, Woolfson DN
Publikováno v: Journal of the American Chemical Society [J Am Chem Soc] 2013 Aug 28; Vol. 135 (34), pp. 12524-7. Date of Electronic Publication: 2013 Aug 13.
Zobrazit plný text záznamu
9
Akademický článek
Organization of the BcgI restriction-modification protein for the cleavage of eight phosphodiester bonds in DNA.
Autor: Smith RM; The DNA-proteins Interaction Unit, School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK., Marshall JJ, Jacklin AJ, Retter SE, Halford SE, Sobott F
Publikováno v: Nucleic acids research [Nucleic Acids Res] 2013 Jan 07; Vol. 41 (1), pp. 391-404. Date of Electronic Publication: 2012 Nov 11.
Zobrazit plný text záznamu
10
Akademický článek
Organization of the BcgI restriction-modification protein for the transfer of one methyl group to DNA.
Autor: Smith RM; The DNA-protein Interactions Unit, School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK., Jacklin AJ, Marshall JJ, Sobott F, Halford SE
Publikováno v: Nucleic acids research [Nucleic Acids Res] 2013 Jan 07; Vol. 41 (1), pp. 405-17. Date of Electronic Publication: 2012 Nov 11.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje